Clinical trials of the Sputnik V coronavirus vaccine will involve 350 children and adolescents aged 12 to 17, said Alexander Gintsburg, director of the Gamaleya Center. According to him, a certain concentration of the vaccine will be selected for each age group.
He clarified that, in general, studies of the drug for adolescents will not differ from those conducted for adults. “Except that there will be different concentrations of Sputnik V for each age … If the effectiveness of the diluted dose is sufficient, then we will stop there,” Mr. Gunzburg told TASS.
He added that the side effects from the vaccine “will be minimal.” Registration of the drug for adolescents is planned for September 20, the vaccine will have a separate registration certificate.
Research on Sputnik V for adolescents will begin in Moscow in July and will last for a year. The first two phases will take place on the basis of the Morozov Children's Hospital and the Bashlyaeva Children's Hospital, the third – in children's polyclinics in Moscow. After the introduction of the first and second components, the adolescents will be in the hospital in an isolated box for three days.
This week, the World Health Organization (WHO) approved the COVID-19 vaccine in adolescents. Previously, WHO argued that patients under 18 years of age should not be vaccinated, as there is insufficient data on the safe use of drugs for this category.
Details – in the material “b” “Vaccinations reduce age.”
Read also:
